• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西班牙裔美国人中,特定族群的血浆和肝内脂质组学特征的改变与非酒精性脂肪性肝病(NAFLD)的高发率和严重程度相关,这是一项初步研究。

Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study.

机构信息

Department of Nutrition, University of California Davis, 3135 Meyer Hall, One Shields Avenue, Davis, CA, 95616, USA; Department of Community Health Sciences-Clinical Nutrition, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh, 11433, Saudi Arabia.

West Coast Metabolomic Center, Genome Center, University of California-Davis, Davis, CA, 95616, USA.

出版信息

Free Radic Biol Med. 2021 Aug 20;172:490-502. doi: 10.1016/j.freeradbiomed.2021.06.024. Epub 2021 Jun 25.

DOI:10.1016/j.freeradbiomed.2021.06.024
PMID:34182070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8712226/
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a progressive condition that includes steatosis (NAFL) and nonalcoholic steatohepatitis (NASH). In the U.S., Hispanics (HIS) are afflicted with NAFLD at a higher rate and severity compared to other ethnicities. To date, the mechanisms underlying this disparity have not been elucidated. In this pilot study, we compared untargeted plasma metabolomic profiles for primary metabolism, complex lipids, choline and related compounds between a group of HIS (n = 7) and White Caucasian (CAU, n = 8) subjects with obesity and biopsy-characterized NAFL to ethnicity-matched lean healthy controls (n = 14 HIS and 8 CAU). We also compared liver and plasma metabolomic profiles in a group of HIS and CAU subjects with obesity and NASH of comparable NAFLD Activity Scores, to BMI-matched NASH-free subjects in both ethnicities. Results highlight signs of metabolic dysregulation observed in HIS, independent of obesity, including higher plasma triglycerides, acylcarnitines, and free fatty acids. With NASH progression, there were ethnicity-related differences in the hepatic profile, including higher free fatty acids and lysophospholipids seen in HIS, suggesting lipotoxicity is involved in the progression of NASH. We also observed greater hepatic triglyceride content, higher plasma triglyceride concentrations and lower hepatic phospholipids with signs of impaired hepatic mitochondrial β-oxidation. These findings provide preliminary evidence indicating ethnicity-related variations that could potentially modulate the risk for progression of NALD to NASH.

摘要

非酒精性脂肪性肝病 (NAFLD) 是一种进行性疾病,包括脂肪变性 (NAFL) 和非酒精性脂肪性肝炎 (NASH)。在美国,与其他族裔相比,西班牙裔 (HIS) 患 NAFLD 的比例更高,病情更严重。迄今为止,导致这种差异的机制尚未阐明。在这项初步研究中,我们比较了一组肥胖且经活检证实存在非酒精性脂肪性肝病的 HIS(n=7)和白种高加索人(CAU,n=8)与同种族的健康对照组(n=14 HIS 和 8 CAU)之间的初级代谢物、复合脂质、胆碱和相关化合物的非靶向血浆代谢组学图谱。我们还比较了一组肥胖且存在非酒精性脂肪性肝炎的 HIS 和 CAU 与同种族、体重指数匹配且不存在非酒精性脂肪性肝炎的非酒精性脂肪性肝炎患者的肝脏和血浆代谢组学图谱。结果突出了在 HIS 中观察到的代谢失调迹象,与肥胖无关,包括更高的血浆甘油三酯、酰基肉碱和游离脂肪酸。随着 NASH 的进展,肝脏图谱存在与种族相关的差异,包括 HIS 中更高的游离脂肪酸和溶血磷脂,表明脂毒性参与了 NASH 的进展。我们还观察到肝组织甘油三酯含量增加、血浆甘油三酯浓度升高和肝磷脂减少,提示肝线粒体 β-氧化受损。这些发现提供了初步证据,表明与种族相关的差异可能会影响从 NALD 进展为 NASH 的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/c03af26ae2c1/nihms-1763478-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/476b3e1f87c7/nihms-1763478-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/af0e3cfec858/nihms-1763478-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/0fd78e2e9b73/nihms-1763478-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/0bb679b00c04/nihms-1763478-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/ab470031972c/nihms-1763478-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/9d9e62364147/nihms-1763478-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/8d302bda10fe/nihms-1763478-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/0f7e0e5c1a11/nihms-1763478-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/c03af26ae2c1/nihms-1763478-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/476b3e1f87c7/nihms-1763478-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/af0e3cfec858/nihms-1763478-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/0fd78e2e9b73/nihms-1763478-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/0bb679b00c04/nihms-1763478-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/ab470031972c/nihms-1763478-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/9d9e62364147/nihms-1763478-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/8d302bda10fe/nihms-1763478-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/0f7e0e5c1a11/nihms-1763478-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc8/8712226/c03af26ae2c1/nihms-1763478-f0010.jpg

相似文献

1
Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study.西班牙裔美国人中,特定族群的血浆和肝内脂质组学特征的改变与非酒精性脂肪性肝病(NAFLD)的高发率和严重程度相关,这是一项初步研究。
Free Radic Biol Med. 2021 Aug 20;172:490-502. doi: 10.1016/j.freeradbiomed.2021.06.024. Epub 2021 Jun 25.
2
Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis.血浆氧化脂质谱可区分非酒精性脂肪性肝炎患者的种族:一项探索性分析。
Metabolites. 2022 Feb 19;12(2):192. doi: 10.3390/metabo12020192.
3
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.严重肥胖症中的肝脂质组学重塑表现为脂肪变性,且不会随着非酒精性脂肪性肝炎而进展。
J Hepatol. 2021 Sep;75(3):524-535. doi: 10.1016/j.jhep.2021.04.013. Epub 2021 Apr 20.
4
LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.基于 LC-MS 的脂质组学分析在鉴别非酒精性脂肪性肝炎与非酒精性脂肪肝患者中的应用。
Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):452-459. doi: 10.1016/j.hbpd.2021.05.008. Epub 2021 Jun 25.
5
The plasma lipidomic signature of nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的血浆脂质组学特征
Hepatology. 2009 Dec;50(6):1827-38. doi: 10.1002/hep.23229.
6
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.与健康正常体重个体相比,不同程度非酒精性脂肪性肝病患者的肝转录组特征。
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.
7
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.非酒精性脂肪性肝病与肝纤维化分期。
Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18.
8
Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.西方饮食诱导的 LDLR-/- 雌性小鼠非酒精性脂肪性肝炎(NASH)的脂质组学和转录组学分析。
PLoS One. 2019 Apr 3;14(4):e0214387. doi: 10.1371/journal.pone.0214387. eCollection 2019.
9
Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.种族在非酒精性脂肪性肝炎超重和肥胖患者中的作用。
Hepatology. 2011 Sep 2;54(3):837-45. doi: 10.1002/hep.24483. Epub 2011 Aug 8.
10
Concise review of lipidomics in nonalcoholic fatty liver disease.非酒精性脂肪性肝病的脂质组学简述。
Diabetes Metab. 2023 May;49(3):101432. doi: 10.1016/j.diabet.2023.101432. Epub 2023 Feb 11.

引用本文的文献

1
Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence, Diagnosis, Treatment, and Outcomes: A Narrative Review.代谢功能障碍相关脂肪性肝病在患病率、诊断、治疗及预后方面的差异:一项叙述性综述
Dig Dis Sci. 2025 Jan;70(1):154-167. doi: 10.1007/s10620-024-08722-0. Epub 2024 Nov 19.
2
Fibroblast Growth Factor 21: A More Effective Biomarker Than Free Fatty Acids and Other Insulin Sensitivity Measures for Predicting Non-alcoholic Fatty Liver Disease in Saudi Arabian Type 2 Diabetes Patients.成纤维细胞生长因子21:在预测沙特阿拉伯2型糖尿病患者非酒精性脂肪性肝病方面,比游离脂肪酸及其他胰岛素敏感性指标更有效的生物标志物。
Cureus. 2023 Dec 14;15(12):e50524. doi: 10.7759/cureus.50524. eCollection 2023 Dec.
3

本文引用的文献

1
One-Carbon Metabolism in Fatty Liver Disease and Fibrosis: One-Carbon to Rule Them All.脂肪性肝病和肝纤维化中的一碳代谢:一碳代谢统御全局。
J Nutr. 2020 May 1;150(5):994-1003. doi: 10.1093/jn/nxaa032.
2
Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro.代谢组学分析鉴定体外甲氨蝶呤细胞反应的分子生物标志物。
Clin Transl Sci. 2020 Jan;13(1):137-146. doi: 10.1111/cts.12694. Epub 2019 Oct 25.
3
Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective.
应用脂质组学研究非酒精性脂肪性肝病:临床视角。
Nutrients. 2023 Apr 20;15(8):1992. doi: 10.3390/nu15081992.
4
Medium Roasting and Brewing Methods Differentially Modulate Global Metabolites, Lipids, Biogenic Amines, Minerals, and Antioxidant Capacity of Hawai'i-Grown Coffee ().中度烘焙和冲泡方法对夏威夷种植咖啡的全球代谢物、脂质、生物胺、矿物质和抗氧化能力有不同程度的调节作用。
Metabolites. 2023 Mar 10;13(3):412. doi: 10.3390/metabo13030412.
5
Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges.成纤维细胞生长因子治疗非酒精性脂肪性肝病:机遇与挑战。
Int J Mol Sci. 2023 Feb 26;24(5):4583. doi: 10.3390/ijms24054583.
6
Influence of non-alcoholic fatty liver disease on non-variceal upper gastrointestinal bleeding: A nationwide analysis.非酒精性脂肪性肝病对非静脉曲张性上消化道出血的影响:一项全国性分析。
World J Hepatol. 2023 Jan 27;15(1):79-88. doi: 10.4254/wjh.v15.i1.79.
7
Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis.血浆氧化脂质谱可区分非酒精性脂肪性肝炎患者的种族:一项探索性分析。
Metabolites. 2022 Feb 19;12(2):192. doi: 10.3390/metabo12020192.
8
Preparation of fatty acid solutions exerts significant impact on experimental outcomes in cell culture models of lipotoxicity.脂肪酸溶液的制备对脂毒性细胞培养模型的实验结果有重大影响。
Biol Methods Protoc. 2021 Dec 3;7(1):bpab023. doi: 10.1093/biomethods/bpab023. eCollection 2022.
美国糖尿病患者使用他汀类药物后残余高甘油三酯血症与估计的动脉粥样硬化性心血管疾病风险:2007-2014 年全国健康和营养调查。
Diabetes Care. 2019 Dec;42(12):2307-2314. doi: 10.2337/dc19-0501. Epub 2019 Oct 1.
4
Mechanisms of NAFLD development and therapeutic strategies.非酒精性脂肪性肝病发病机制及治疗策略。
Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2.
5
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.乙酰辅酶 A 羧化酶抑制剂 GS-0976 治疗 12 周可降低非酒精性脂肪性肝炎患者肝脏从头合成脂肪和脂肪变性。
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1983-1991.e3. doi: 10.1016/j.cgh.2018.04.042. Epub 2018 Apr 26.
6
CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.CD36 的棕榈酰化作用破坏游离脂肪酸代谢并促进非酒精性脂肪性肝炎中的组织炎症。
J Hepatol. 2018 Sep;69(3):705-717. doi: 10.1016/j.jhep.2018.04.006. Epub 2018 Apr 27.
7
Chemical Similarity Enrichment Analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets.化学相似性富集分析(ChemRICH)作为代谢组学数据集的生化途径映射替代方法。
Sci Rep. 2017 Nov 6;7(1):14567. doi: 10.1038/s41598-017-15231-w.
8
Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?胰岛素抵抗与代谢灵活性降低:非酒精性脂肪性肝病的原因还是后果?
Clin Sci (Lond). 2017 Nov 6;131(22):2701-2704. doi: 10.1042/CS20170987. Print 2017 Nov 15.
9
Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.美国非酒精性脂肪性肝病患病率、严重程度和结局的种族和民族差异:系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2018 Feb;16(2):198-210.e2. doi: 10.1016/j.cgh.2017.09.041. Epub 2017 Sep 29.
10
Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes.非酒精性脂肪肝的代谢紊乱类似于 2 型糖尿病的典型改变。
Clin Sci (Lond). 2017 Jul 7;131(15):1905-1917. doi: 10.1042/CS20170261. Print 2017 Aug 1.